Agios Pharmaceuticals' stock surged 6.07% in pre-market trading on Wednesday after the company reported first-quarter financial results that significantly exceeded analyst expectations.

The biopharmaceutical firm posted a quarterly loss of $1.69 per share, which was better than the consensus estimate for a loss of $1.79 per share. More notably, revenue for the quarter reached $20.75 million, more than doubling from the same period last year and beating the average analyst estimate of approximately $13.6 million by a wide margin.

The strong revenue performance was primarily driven by the successful U.S. commercial launch of its drug AQVESME (mitapivat) for thalassemia in late January 2026, along with continued demand for its product PYRUKYND in international markets.